Randox Signs Principal Partnership with Sheffield United FC
26th May 2021 – Randox Signs Principal Partnership with Sheffield United FC
Global innovative healthcare company and the UK’s largest COVID-19 PCR testing provider Randox is today pleased to announce that it has signed a three-year principle partnership agreement with Sheffield United. The partnership will commence in the 2021 /2022 season and will include both men’s and women’s first team. From next season both teams will wear the Randox logo on their jerseys.
Founded in 1982 in County Antrim by leading medical scientist, Dr. Peter FitzGerald CBE, Randox has been a pioneer in improving health and enhancing lives, worldwide. To achieve their goals the company is committed to an extensive research programme, including investing more than £300m in the development of its innovative biochip array programme to enable earlier, more accurate diagnosis. The company currently employs more than 2000 people of over 40 different nationalities.
Randox is a world leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis through use of Randox products each year. Over the past year, Randox has been at the forefront of the UK’s fight against COVID-19, and has significantly invested in its testing capacity meaning that it can now process over 500,000 tests per day, making it amongst the very largest COVID-19 laboratories in Europe. To date Randox having processed over 13 million COVID-19 PCR tests in the UK and now have comprehensive Covid-19 testing, logistics and customer services available to support overseas holidays and those undertaking international travel.
Randox has a proud history of supporting sports, and has been the Official Partner of the, the Grand National since 2017.
Dr. Peter FitzGerald CBE, Randox Chief Executive Officer, said;
“We are very excited about this partnership and the opportunity to align Randox with Sheffield United Football Club. Not only is Sheffield the birthplace of football, but it is also one of the fastest growing cities in developing sports science and medical technology which we are very keen to see how we can look to assist through our services. We are extremely proud to be the principal partner of the Blades and to be a part of the club’s progress in the years to come.”
For press enquiries please contact Amy Millar in the Randox PR team on firstname.lastname@example.org or 028 9442 2413
Want to know more?
Contact us or visit Randox Health.
Related COVID-19 Products and Services
TEST TO RELEASE
The RIQAS Neonatal Bilirubin EQA programme has been designed to assess the performance of total and direct bilirubin assays with levels tailored to neonatal bilirubin testing.
- Lyophilised for enhanced stability
- Monthly reporting
- Human based serum
- Submit results and view reports online via RIQAS.net
- Rapid turnaround of reports allows for any necessary corrective actions to be taken with minimal disruption to laboratory output
Not accredited to ISO/IEC 17043
- Direct Bilirubin
- Total Bilirubin
Please note, product availability may vary country to country.
The Silent Pandemic
A striking statistic is that an estimated 4.2 million people die annually from Diabetes complications and it is anticipated it will be the seventh leading cause of death by 2030.
Type 2 diabetes mellitus (T2DM) has reached the status of ‘global pandemic’, a phrase we have become all too familiar with due to the current global Covid-19 pandemic, but one we now know not take for granted.
Diabetes is a chronic, potentially life-threatening disease and can cause a myriad of health complications which affect the feet, eyes, kidneys, and cardiovascular health.
Early detection and treatment of diabetes is key, particularly as many people with type 2 diabetes have no signs or symptoms but do have associated risk factors.
Randox is committed to raising awareness of preventative healthcare related to Diabetes through advancing diabetes testing capabilities, including diabetes diagnosis & monitoring, and monitoring of associated complications including; ketoacidosis, renal dysfunction, and metabolic status.
The Randox Diabetes testing panel consists of ten assays including niche and superior performance assays that are compatible with a wide range of clinical chemistry analyzers.
Find out more about the Randox diabetes reagents panel or alternatively you can contact us
Product availability may vary from country to country. Some products may be for research use only. For more information on product application & availability, please contact your local Randox Representative
Diabetes Reagents Panel
Diagnosis & Monitoring
In the clinical laboratory, Quality Control (QC) refers to the process of detecting analytical errors to ensure both the reliability and accuracy of patient test results. Poor performance can result in misdiagnosis, delayed/inappropriate treatment, increased costs and may even be potentially life threatening for the patient. Third party controls offer a better solution to ensure optimum performance and accuracy.
When the laboratory professional runs the QC material on their instrument, they can compare the obtained result with the expected result. If these values are comparable, then the laboratory professional can be confident that their instrument is reporting accurately. Essentially, QC is a ‘practice run’ to ensure the testing system is working correctly.
Benefits Of Using Third-Party Controls
Third party controls have been designed to deliver an independent, unbiased assessment of performance with any instrument or method helping you gain accreditation. Below are some of the key benefits of third party controls:
- Values assigned using a large number of independent laboratories ensuring statistically valid targets.
- Highly consolidated controls allow for space, time, and ultimately, cost savings.
- Boosted shelf life ensures continuity of supply and reduced costs
- Reduced preparation times by removing the need for multiple instrument controls
Importance Of Third-Party Controls In The Midst Of COVID-19
Quality Control is a hugely important part of laboratory quality. Around 70% of clinical decisions are made based on laboratory results, so it is plain to see how significant Quality Control practices can be in relation to global health care. Having faith in the performance of the Quality Control used within the lab, as well as benefits gained from highly consolidated controls, allow for space, time, and ultimately, cost savings. These benefits would prove highly beneficial for any laboratory operating in the fast-paced environment posed by the pandemic.
How Randox Can Help
Randox Acusera true third party quality controls offer complete test menu consolidation for laboratory Internal Quality Control. Providing accurate and reliable sample material and delivering results you can trust.
Find out more: https://www.randox.com/laboratory-quality-control-acusera/
Want to know more?
Contact us or visit our Acusera page to learn more.
Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
The Randox Discovery, an exciting and unique diagnostic analyser which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High Design Quality.
Red Dot, which has become established as one of the top profile product design awards has roots dating back as far as 1955 and determines the best products created each year. Recognised as one of the largest global product competitions for innovation excellence, this sought-after seal for quality design attracts submissions from over 50 countries, across 49 different categories including medical devices and technology.
Dr Stuart Jackson, Randox Project Design Engineer, commented;
“Randox are delighted to have achieved the Red Dot design award, the culmination of five years of development and coordination of engineering design teams spanning two continents. The Discovery is a particularly unique innovation capable of automating Randox Biochip molecular diagnostics assays, from sample lysis and end-point PCR to multiplexing detection, with accessibility and ease-of-use at the forefront of the design.”
Dolmen were briefed by the Randox team to develop a creative and dynamic way to showcase the cutting-edge inner workings of the Discovery. Essentially, to turn the magic of the machine into a piece of theatre; not just a tool, but the centre of attention, a focal point for the lab that has excellent usability and accessibility throughout. Dolmen and Randox collaborated closely to deliver a revolutionary instrument that, amongst its many abilities, is a COVID-19 diagnostic analyser that is the first of its kind.
Chris Murphy, CEO and Design Director, Dolmen Design and Innovation, commented;
“We are delighted that our collaboration with Randox has delivered another Red Dot design award for our team. Randox as a team truly value the power of design and how it can deliver better outcomes for end users. It is also wonderful to see our designs delivering positive change at the frontline of the COVID pandemic. This project was hugely collaborative, and we look forward to more collaborations in the future.”
What makes the Discovery special is its ability to conduct the full testing process, inclusive of sample preparation techniques such as extraction, purification, amplification and detection, in one highly intelligent, fully integrated space. The preparation of COVID-19 samples before testing was once lengthy and time-consuming, requiring a separate, sterilized laboratory for each stage, but can now be conducted on-board and by the fully automated Discovery platform, allowing a single operator to run multiple molecular tests simultaneously.
Combining almost 40 years of diagnostics into one platform, bringing multiple labs into one the COVID-19 diagnostic analyser is the first of its kind to combine sample preparation techniques and Biochip Technology.
Professor Dr. Peter Zec, Red Dot CEO, commented;
“The winners of the Red Dot Award: Product Design 2021 were particularly impressive this year. The design of their products is excellent, in terms of both the aesthetic and the functionality. It’s not easy to prevail in such a strong field of competitors and to win over our jury. Consequently, I want to congratulate the laureates very sincerely on their success.”
For further information please email email@example.com
Want to know more?
Contact us or visit our find out more about the Randox Discovery
COVID 19 Product Overview
COVID 19 QPCR ASSAY
VIRAL RNA EXTRACTION KIT
14 April 2021: Banned substance furazolidone (AOZ) detected in shrimp at French border
As per an alert through RASFF – the Rapid Alert System for Food and Feed for the EU, shrimp imported from India has been rejected at the French border in March 2021 for containing a banned substance, known as furazolidone (AOZ). The shrimp product has since been destroyed and did not make it into the market for distribution.
Nitrofuran antibiotics, the parent compound of AOZ, were banned for use in animal food production in the EU in 1995 and 2009 in the US for its reported carcinogenic and mutagenic characteristics. However due to the drugs low cost and effectiveness in controlling disease it is still in use despite the ban.
Randox Food Diagnostics
Randox Food Diagnostics have developed a highly accurate and reliable immunoassay array which detects Nitrofuran residues including AOZ, AMOZ, AHD and SEM.
Available on the Evidence Investigator, our Antimicrobial Array III utilises our patented Biochip Array Technology which provides screening of up to 54 meat and seafood samples. The Evidence Investigator provides results for multiple drug residues and toxins in just 2.5 hours, saving the user both time and money compared to other screening and confirmatory methods.
Randox Food Diagnostics also provide a vast variety of ELISA kits to test for antibiotics in meat and seafood tissue, offering excellent cross-reactivity and unrivalled limits of detection. With results providing great correlation with confirmatory methods, we ensure that better science means safer food.
Want to know more?
For more information on tissue screening methods from Randox Food Diagnostics please visit the links below.
Alternatively contact us via email: firstname.lastname@example.org
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Meat & Seafood
11th March 2021 is World Kidney Day, a worthy global campaign aimed at tackling “the hot topic everyone’s ignoring”.
Raising awareness of a disease that ‘one in every nine’ people worldwide suffer from, is something we take seriously.
Here at Randox, our vision is to improve healthcare worldwide and ensure patients across the globe have access to the latest advancements in clinical diagnostics to tackle diseases such as Chronic Kidney Disease.
This year World Kidney Day 2021 focuses on being able to live well with kidney disease. Many of us take for granted being able to live a normal life without the side effects such as fatigue, pain, depression, sleep problems etc. However Kidney disease can be huge challenge patients and those around them. The impacts of kidney disease can take a toll of day to day life and the ability to participate in activities such as work, travel, and socialising.
Kidney diseases are very common and can be harmful, but the good news is they are also very treatable!
Randox offer a comprehensive panel of kidney health tests, working to ensure timely and accurate diagnosis of kidney function problems to combat patient challenges early.
For example, low levels of albumin indicate signs of kidney damage in the early stages when diagnosis is key. Testing for albumin can identify individuals with diabetic nephropathy (damage to the kidneys caused by diabetes) around 10 years earlier than standard protein tests. The Randox albumin test can therefore enable preventative measures to be taken to reduce your risk of developing kidney disease.
With early diagnosis we can improve patient treatment outcomes and reduce the number of people across the world suffering with kidney health problems.
If you want to find out the status of your own Kidney Health, book a health check with Randox Health today.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Dog Food Recalled Due to Potentially Unsafe Levels of Aflatoxin
The importance of screening food for toxins has been highlighted this month with the recent news that Midwestern Pet Foods Inc. have extended their product recall after reports that the pet food has potentially caused the deaths of 70 dogs due to containing possibly unsafe levels of aflatoxin.
The Food and Drug Administration said in a statement that it has been “aware of more than 70 dogs that have died and more than 80 that are sick after eating Sportmix pet food.”
Aflatoxins are mycotoxins produced by two species of Aspergillus, a fungus which is especially found in areas with hot and humid climates. Aflatoxins have a wide occurrence in feed and cereals, such as wheat, barley, rice and corn, which are used as ingredients in pet food. At high levels, aflatoxin can cause illness and death in animals.
Midwestern Pet Foods first announced a voluntary recall on Dec. 30, extending it last week. “There have been reports of illnesses and deaths in dogs associated with certain lots of products. No human illnesses have been reported,” the company said in a recall announcement. “Out of an abundance of caution, we have expanded this recall to cover all corn products containing pet foods with expiration dates prior to 07/09/22.”
Aflatoxin poisoning can display in animals with symptoms such as sluggishness, loss of appetite, vomiting, jaundice and diarrhoea.
The expanded recall includes “additional corn-containing lot codes of Sportmix, Pro Pac Originals, Splash, Sportstrail, and Nunn Better dry dog and cat foods” that were produced in its Oklahoma manufacturing plant. A full list of recalled products can be found here.
Randox Food Diagnostics
Randox provide solutions to the agricultural industry by having developed a range of screening platforms for toxins and drug residues within feed and cereals. Multiple mycotoxins can affect crops and drug residues can pass through to feed causing adverse health effects in both humans and animals.
Myco 9 facilitates the detection of up to 9 common mycotoxins from a single sample of cereal or cereal based feed, including aflatoxin B1/B2, aflatoxin G1/G2, deoxynivalenol, diacetoxyscirpenol, fumonisins, ochratoxin A, paxilline, T2 toxin & zearalenone.
For more information on the antibiotic screening arrays available contact us at: email@example.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Meat & Seafood
21st December 2020
Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours
Randox Laboratories is proud to announce the launch of its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both of the leading COVID-19 diagnostic antigens – Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP).
Maximum test sensitivity is ensured through simultaneous detection of both RBD-only and NP-only responders, making it superior to current commercially available COVID-19 IgG tests that are based on RBD or NP alone, from which false negative results can occur.
The Randox SARS-CoV-2 IgG (RBD & NP) Array provides clinicians with an opportunity to discriminate vaccinated individuals from those naturally infected by COVID-19.
Lynsey Adams, Randox Clinical Marketing Manager commented;
“When there is little or no access to molecular testing, serology tests provide a means to quickly triage suspected cases of COVID-19, enabling appropriate case management, and guiding public health measures, such as quarantine or self-isolation.
“The new Randox SARS-CoV-2 IgG (RBD & NP) Array, provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID-19 pandemic progresses.”
The Randox SARS-CoV-2 IgG (RBD & NP) Array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser delivering accurate results in just 1.5 hours.
Features of the new Randox SARS-CoV-2 IgG (RBD & NP) Array
- Utilises established diagnostic antigen candidates – RBD and NP
- IgG measurement confirms adaptive immune response to SARS-CoV-2
- Clinical specificity of 99.5%
- Clinical sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
- Dual sample matrix: human serum/plasma.